Arcutis Biotherapeutics, Inc. $ARQT Stock Bought by Candriam S.C.A.

Candriam S.C.A. grew its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) by 5.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,003,729 shares of the company’s stock after purchasing an additional 53,890 shares during the period. Candriam S.C.A.’s holdings in Arcutis Biotherapeutics were worth $26,625,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in ARQT. Bank of America Corp DE increased its position in shares of Arcutis Biotherapeutics by 32.7% during the 1st quarter. Bank of America Corp DE now owns 2,221,289 shares of the company’s stock worth $52,334,000 after purchasing an additional 547,835 shares in the last quarter. Tejara Capital Ltd bought a new position in Arcutis Biotherapeutics during the 2nd quarter valued at about $2,965,000. Kornitzer Capital Management Inc. KS lifted its holdings in Arcutis Biotherapeutics by 55.1% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 175,870 shares of the company’s stock valued at $4,143,000 after purchasing an additional 62,485 shares during the last quarter. Sei Investments Co. lifted its holdings in Arcutis Biotherapeutics by 97.7% during the 1st quarter. Sei Investments Co. now owns 206,141 shares of the company’s stock valued at $4,857,000 after purchasing an additional 101,855 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in Arcutis Biotherapeutics in the second quarter valued at about $2,643,000.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ARQT shares. Morgan Stanley raised their price objective on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Needham & Company LLC set a $40.00 target price on Arcutis Biotherapeutics in a report on Thursday. Jefferies Financial Group restated a “buy” rating and set a $39.00 price target on shares of Arcutis Biotherapeutics in a research report on Thursday, October 8th. Guggenheim increased their price target on Arcutis Biotherapeutics from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. Finally, Wall Street Zen cut Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.75.

Arcutis Biotherapeutics Stock Performance

ARQT stock opened at $25.55 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.92 and a quick ratio of 2.66. The company has a 50 day moving average price of $27.16 and a 200 day moving average price of $25.37. Arcutis Biotherapeutics, Inc. has a fifty-two week low of $19.30 and a fifty-two week high of $34.80. The stock has a market capitalization of $3.22 billion, a PE ratio of 121.67 and a beta of 1.66.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.12). The firm had revenue of $143.92 million during the quarter, compared to the consensus estimate of $142.59 million. Arcutis Biotherapeutics had a net margin of 5.88% and a return on equity of 14.18%. Analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.33 EPS for the current year.

Insider Activity at Arcutis Biotherapeutics

In other news, EVP Masaru Matsuda sold 40,000 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $34.32, for a total transaction of $1,372,800.00. Following the transaction, the executive vice president owned 111,289 shares of the company’s stock, valued at $3,819,438.48. This represents a 26.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Patrick Burnett sold 943 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $31.86, for a total value of $30,043.98. Following the completion of the transaction, the executive vice president owned 116,649 shares in the company, valued at approximately $3,716,437.14. This represents a 0.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 123,932 shares of company stock valued at $3,553,077 over the last quarter. 9.40% of the stock is currently owned by corporate insiders.

Key Stories Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis raised its 2026 sales guidance, a sign of improved commercial expectations. However, investors may be weighing whether the stronger outlook is already reflected in the stock. Article: Arcutis Biotherapeutics Raised 2026 Sales Guidance
• Positive Sentiment: The company began enrolling participants in a Phase 3 study of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the medicine’s potential market, though this remains a clinical-development catalyst. Article: Arcutis Begins Enrolling Phase 3 ZORYVE Study
• Neutral Sentiment: Arcutis granted stock options and restricted stock units to six new employees. The awards create some share dilution, but are routine hiring-related inducements and are not a major business update. Article: Arcutis Reports Inducement Grants
• Negative Sentiment: Third-quarter EPS was $0.06, below analyst expectations of roughly $0.17–$0.18. Revenue of $143.92 million narrowly topped forecasts, but the earnings miss appears to be the more immediate sentiment driver. Article: Arcutis Falls After Q3 Earnings Miss
• Negative Sentiment: HC Wainwright cut its EPS estimates for the first three quarters of 2027, including reducing its Q2 forecast from $0.19 to $0.14. The lowered projections add to concerns following the quarterly earnings shortfall.

Arcutis Biotherapeutics Profile

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California.

Arcutis primarily serves the U.S.